Journal for ImmunoTherapy of Cancer (Aug 2021)
LINC01140 promotes the progression and tumor immune escape in lung cancer by sponging multiple microRNAs
- Jing Guo,
- Jie Jiang,
- Rongmu Xia,
- Guojun Geng,
- Xiuyi Yu,
- Zhong Xu,
- Hongming Liu,
- Ziyan Li,
- Yingli Li,
- Xiaofang Dai,
- Qicong Luo,
- Yanjun Mi
Affiliations
- Jing Guo
- Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University; School of Clinical Medicine, Fujian Medical University, Xiamen 361003, Fujian Province, China
- Jie Jiang
- Department of Thoracic Surgery, Xiamen Key Laboratory of Thoracic tumor diagnosis and treatment, Institute of lung cancer, The First Affiliated Hospital of Xiamen University; School of clinical Medicine, Fujian Medical University, Xiamen 361003, Fujian Province, China
- Rongmu Xia
- Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University; School of Clinical Medicine, Fujian Medical University, Xiamen 361003, Fujian Province, China
- Guojun Geng
- Department of Thoracic Surgery, Xiamen Key Laboratory of Thoracic tumor diagnosis and treatment, Institute of lung cancer, The First Affiliated Hospital of Xiamen University; School of clinical Medicine, Fujian Medical University, Xiamen 361003, Fujian Province, China
- Xiuyi Yu
- Department of Thoracic Surgery, Xiamen Key Laboratory of Thoracic tumor diagnosis and treatment, Institute of lung cancer, The First Affiliated Hospital of Xiamen University; School of clinical Medicine, Fujian Medical University, Xiamen 361003, Fujian Province, China
- Zhong Xu
- Department of Thoracic Surgery, Xiamen Key Laboratory of Thoracic tumor diagnosis and treatment, Institute of lung cancer, The First Affiliated Hospital of Xiamen University; School of clinical Medicine, Fujian Medical University, Xiamen 361003, Fujian Province, China
- Hongming Liu
- Department of Thoracic Surgery, Xiamen Key Laboratory of Thoracic tumor diagnosis and treatment, Institute of lung cancer, The First Affiliated Hospital of Xiamen University; School of clinical Medicine, Fujian Medical University, Xiamen 361003, Fujian Province, China
- Ziyan Li
- Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University; School of Clinical Medicine, Fujian Medical University, Xiamen 361003, Fujian Province, China
- Yingli Li
- Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University; School of Clinical Medicine, Fujian Medical University, Xiamen 361003, Fujian Province, China
- Xiaofang Dai
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
- Qicong Luo
- Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University; School of Clinical Medicine, Fujian Medical University, Xiamen 361003, Fujian Province, China
- Yanjun Mi
- Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University; School of Clinical Medicine, Fujian Medical University, Xiamen 361003, Fujian Province, China
- DOI
- https://doi.org/10.1136/jitc-2021-002746
- Journal volume & issue
-
Vol. 9,
no. 8
Abstract
No abstracts available.
